House Loses Medical Device Reform Architect To BIO
This article was originally published in The Gray Sheet
Executive Summary
Rep. Jim Greenwood's (R-Penn.) experience drafting combination product legislation suggests BIO will be alert to shared opportunities in the biologics/device policy arena
You may also be interested in...
FDA Conflict Of Interest Policies Will Be Reviewed By House Committee
The House Energy & Commerce Committee will review FDA's conflict-of-interest procedures as part of an expanding probe that originally focused on National Institutes of Health employee consulting arrangements
Medtronic Gets To Heart Of Cell Therapy Through Genzyme Collaboration
Medtronic will draw on expertise from its three cardiac-related divisions to aid Genzyme in the development of a catheter-delivered cell therapy for cardiovascular disease
Future Of Medical Liability, CMS Reforms May Ride On House Rx Drug Bill
Rep. James Greenwood (R-Penn.) is exhorting device companies to convey to the Senate that medical liability reforms, including a product liability provision, are crucial to their industry